ATE396712T1 - Pharmazeutische zubereitung zur modifizierten freisetzung - Google Patents

Pharmazeutische zubereitung zur modifizierten freisetzung

Info

Publication number
ATE396712T1
ATE396712T1 AT03777508T AT03777508T ATE396712T1 AT E396712 T1 ATE396712 T1 AT E396712T1 AT 03777508 T AT03777508 T AT 03777508T AT 03777508 T AT03777508 T AT 03777508T AT E396712 T1 ATE396712 T1 AT E396712T1
Authority
AT
Austria
Prior art keywords
modified release
pharmaceutical preparation
coated
granulate
tablet
Prior art date
Application number
AT03777508T
Other languages
English (en)
Inventor
Janez Kerc
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SI200200318A external-priority patent/SI21349A/sl
Priority claimed from SI200300246A external-priority patent/SI21602A/sl
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Application granted granted Critical
Publication of ATE396712T1 publication Critical patent/ATE396712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03777508T 2002-12-24 2003-12-23 Pharmazeutische zubereitung zur modifizierten freisetzung ATE396712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200318A SI21349A (sl) 2002-12-24 2002-12-24 Plavajoča farmacevtska oblika s prirejenim sproščanjem zdravilne učinkovine
SI200300246A SI21602A (sl) 2003-09-24 2003-09-24 Plavajoča farmacevtska oblika s prirejenim sproščanjem zdravilne učinkovine

Publications (1)

Publication Number Publication Date
ATE396712T1 true ATE396712T1 (de) 2008-06-15

Family

ID=32684373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03777508T ATE396712T1 (de) 2002-12-24 2003-12-23 Pharmazeutische zubereitung zur modifizierten freisetzung

Country Status (15)

Country Link
US (1) US7485322B2 (de)
EP (1) EP1578406B1 (de)
AT (1) ATE396712T1 (de)
AU (1) AU2003286994A1 (de)
BR (1) BRPI0317682B1 (de)
CA (1) CA2509976C (de)
DE (1) DE60321386D1 (de)
DK (1) DK1578406T3 (de)
EA (1) EA011373B1 (de)
ES (1) ES2305537T3 (de)
MX (1) MXPA05006916A (de)
PL (1) PL207776B1 (de)
PT (1) PT1578406E (de)
SI (1) SI1578406T1 (de)
WO (1) WO2004058230A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8703943B2 (en) 2010-09-01 2014-04-22 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
MX2013002383A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Sales bromhidrato de una pirazolilaminoquinazolina.
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ,インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10137094B2 (en) 2011-10-11 2018-11-27 Sun Pharmaceutical Industries Limited Gastroretentive dosage system and process of preparation thereof
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
IL291000B2 (en) 2014-03-20 2024-04-01 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN107007838B (zh) * 2016-09-30 2021-07-20 南京优科制药有限公司 一种含有马来酸依那普利、叶酸和酸稳定剂的药物组合物
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1815902A (en) * 1927-07-16 1931-07-28 Nat Aniline & Chem Co Inc Device for administering medicaments
US2340037A (en) * 1941-09-08 1944-01-25 Zipper Alfred Irving Capsule
US3186910A (en) * 1962-03-08 1965-06-01 Jacob A Glassman Method for producing peroral capsules
JPS5512411B2 (de) * 1974-03-12 1980-04-02
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4601896A (en) * 1984-03-21 1986-07-22 Mark Nugent Pharmaceutical capsule compositions and structures for gastric sensitive materials
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US4814178A (en) * 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5387421A (en) * 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
JP2959423B2 (ja) 1994-12-01 1999-10-06 シオノギクオリカプス株式会社 カプセル用皮膜組成物
WO1998050019A1 (en) 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
IL147826A0 (en) * 1999-07-30 2002-08-14 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20030194430A1 (en) * 2002-04-10 2003-10-16 Miller Frederick H. Process for encapsulating multi-phase, multi-compartment capsules for therapeutic compositions

Also Published As

Publication number Publication date
EP1578406B1 (de) 2008-05-28
WO2004058230A1 (en) 2004-07-15
EA200500909A1 (ru) 2006-02-24
EP1578406A1 (de) 2005-09-28
PT1578406E (pt) 2008-09-01
MXPA05006916A (es) 2005-08-18
PL207776B1 (pl) 2011-01-31
DE60321386D1 (de) 2008-07-10
BR0317682A (pt) 2005-11-29
CA2509976C (en) 2012-03-13
ES2305537T3 (es) 2008-11-01
SI1578406T1 (sl) 2009-02-28
DK1578406T3 (da) 2008-09-08
US7485322B2 (en) 2009-02-03
AU2003286994A1 (en) 2004-07-22
PL376099A1 (en) 2005-12-12
US20040131669A1 (en) 2004-07-08
BRPI0317682B1 (pt) 2015-04-14
EA011373B1 (ru) 2009-02-27
CA2509976A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
DE60321386D1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
PT1439829E (pt) Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
MXPA03007712A (es) Sales farmaceuticas.
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
AR033711A1 (es) Composiciones farmaceuticas
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
BG108516A (en) Pharmaceutical formulation
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AU2003240654A1 (en) Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
EP1584335A3 (de) Zusammensetzung aus Aktiva mit einer Carbinolverbindung und einem Opioid
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
WO2004024128A3 (en) Modified release ketoprofen dosage form
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
AU2002238673A1 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
ATE296606T1 (de) Schnell freisetzende farmazeutische darreichungsform enthaltend polymorphes tibolon
ITMI20011457A0 (it) Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1578406

Country of ref document: EP